The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes

NCT07156773 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: XJN010 Nasal Spray
DRUG: Placebo

Sponsor

Guangzhou Novaken Pharm Co., Ltd.